These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35135554)

  • 21. Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices.
    Carlsson H; Hjorton K; Abujrais S; Rönnblom L; Åkerfeldt T; Kultima K
    Arthritis Res Ther; 2020 Jun; 22(1):125. PubMed ID: 32475347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
    Mavrikakis I; Sfikakis PP; Mavrikakis E; Rougas K; Nikolaou A; Kostopoulos C; Mavrikakis M
    Ophthalmology; 2003 Jul; 110(7):1321-6. PubMed ID: 12867385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes.
    Balevic SJ; Cohen-Wolkowiez M; Eudy AM; Green TP; Schanberg LE; Clowse MEB
    J Rheumatol; 2019 Jan; 46(1):57-63. PubMed ID: 30275257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.
    Paniri A; Hosseini MM; Rasoulinejad A; Akhavan-Niaki H
    Eur J Pharmacol; 2020 Nov; 886():173454. PubMed ID: 32763298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.
    Carmichael SJ; Day RO; Tett SE
    Intern Med J; 2013 May; 43(5):547-53. PubMed ID: 23425382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
    Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
    Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capillary Blood Levels of Hydroxychloroquine and Methotrexate Are Stable for up to 5 Years When Collected on Volumetric Absorptive Microsamplers.
    Brady K; Alexander RV; Stimson D; Rudolph M; Kammesheidt A
    J Appl Lab Med; 2021 Jul; 6(4):858-867. PubMed ID: 33555010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis.
    Andrade Balbi V; Artur Silva C; Nascimento Pedrosa T; Maria Rodrigues Pereira R; Maria de Arruda Campos L; Pires Leon E; Duarte N; Melechco Carvalho V; Gofinet Pasoto S; Cordeiro do Rosário D; Kolachinski Brandao L; I Brunner H; Bonfá E; Emi Aikawa N
    Lupus; 2022 Jan; 31(1):97-104. PubMed ID: 34965782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood.
    Charlier B; Pingeon M; Dal Piaz F; Conti V; Valentini G; Filippelli A; Izzo V
    Biomed Chromatogr; 2018 Aug; 32(8):e4258. PubMed ID: 29669398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.
    Sailler L; Puissant B; Méliani P; Castex JO; Saivin S; Adoue D; Fournie B; Arlet P; Montastruc JL; Lapeyre-Mestre M; Pourrat J; Blancher A
    Ann N Y Acad Sci; 2007 Jun; 1108():41-50. PubMed ID: 17893969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.
    Lo CH; Wei JC; Wang YH; Tsai CF; Chan KC; Li LC; Lo TH; Su CH
    Front Immunol; 2021; 12():631869. PubMed ID: 33868251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.
    Yang J; Yang X; Yang J; Li M
    J Rheumatol; 2018 Jun; 45(6):818-826. PubMed ID: 29545450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
    Fairley JL; Nikpour M; Mack HG; Brosnan M; Saracino AM; Pellegrini M; Wicks IP
    Intern Med J; 2023 Mar; 53(3):311-317. PubMed ID: 35969110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
    Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.